33 recruiting, 11 active not recruiting, 8 not yet recruiting, 6 completed. 27 Phase 2, 22 Phase 1, 13 Phase 3.
Follow T-DXd: new trials by email Literature Review of T-DXd trials Research Report on T-DXd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Not yet recruiting | Baptist Health South Florida | 20 | 2027-01-01 | 2026-10-01 |
| Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan Dexamethasone, antiemetic premedication, T-DXd - Breast Cancer, Interstitial Lung Disease (ILD) | Phase 3 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 244 | 2026-12-20 | 2026-10-19 |
| Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer Azeliragon, T-DXd - T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 27 | 2026-12-01 | 2026-08-25 |
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-11-30 | 2026-11-02 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer Fam-Trastuzumab Deruxtecan-Nxki - Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 27 | 2026-10-01 | 2026-10-01 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 100 | 2026-06-01 | 2026-06-05 |
| SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study SHR-A1811, Pyrotinib, Capecitabine - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-03-31 | 2026-02-18 |
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy - Ovarian Cancer, Ovarian Carcinoma, Recurrent | Phase 2 | Recruiting | Yonsei University | 116 | 2026-02-26 | 2026-04-20 |
| Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Digital Health Tools, T-DXd, Pertuzumab - Breast Cancer Stage IV | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 300 | 2026-02-18 | 2026-03-27 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 686 | 2025-10-24 | 2026-10-23 |
| A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting Trastuzumab Deruxtecan, Chemotherapy - Endometrial Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 710 | 2025-09-30 | 2026-10-27 |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel - Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-07-21 | 2026-11-03 |
| A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors Trastuzumab Deruxtecan - Recurrent or Metastatic Solid Tumors | Phase 1 | Recruiting | Daiichi Sankyo | 76 | 2025-07-17 | 2026-07-09 |
Showing 20 of 59. Sign in to see all of them.
Breast Neoplasms (25) · Neoplasm Metastasis (12) · Stomach Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Colonic Neoplasms (3) · Pancreatic Neoplasms (3) · Adenocarcinoma (2) · Brain Neoplasms (2) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Rectal Neoplasms (2) · Recurrence (2) · Salivary Gland Neoplasms (2) · Triple Negative Breast Neoplasms (2)
Daiichi Sankyo (17) · National Cancer Institute (NCI) (10) · AstraZeneca (6) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (2) · Fudan University (2) · Memorial Sloan Kettering Cancer Center (2) · Ana C Garrido-Castro, MD (1) · Baptist Health South Florida (1) · Beijing 302 Hospital (1) · Dana-Farber Cancer Institute (1) · Enliven Therapeutics (1) · Jeeyun Lee (1) · Kristina A. Fanucci (1) · Mario Negri Institute for Pharmacological Research (1) · MedSIR (1)
United States (41) · Spain (23) · Italy (21) · France (19) · South Korea (18) · China (17) · Japan (16) · Taiwan (15) · Belgium (13) · Germany (13) · Brazil (12) · Australia (10) · Poland (9) · United Kingdom (9) · Canada (8)
Funda Meric-Bernstam (2) · Alan L Ho (1) · Ana Garrido-Castro, MD (1) · Andreas N Saltos (1) · Andrew A Davis, MD (1) · Andrew Davis (1) · Antonio Llombart-Cussac, MD (1) · Christine Brezden-Masley (1) · Damon R Reed (1) · Elizabeth K Lee (1) · Filipa Lynce (1)
PMID 37086745, PMID 37597578, PMID 37870536, PMID 38351187, PMID 38592002, PMID 38697155, PMID 39116902, PMID 39261417, PMID 40341124, PMID 40454632, PMID 40976668, PMID 41164130, PMID 41213241, PMID 41342740, PMID 41448488, PMID 41487064, PMID 42131734, PMID 42135959, PMID 42682104
2023 (8), 2025 (3), UM1CA186688 (3), 2018 (2), UM1CA186689 (2), UM1CA186709 (2), 2017 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA228823 (1)